Literature DB >> 16431111

QSAR modeling of mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating dopamine release.

Fang Zheng1, Ersin Bayram, Sangeetha P Sumithran, Joshua T Ayers, Chang-Guo Zhan, Jeffrey D Schmitt, Linda P Dwoskin, Peter A Crooks.   

Abstract

Back-propagation artificial neural networks (ANNs) were trained on a dataset of 42 molecules with quantitative IC50 values to model structure-activity relationships of mono- and bis-quaternary ammonium salts as antagonists at neuronal nicotinic acetylcholine receptors (nAChR) mediating nicotine-evoked dopamine release. The ANN QSAR models produced a reasonable level of correlation between experimental and calculated log(1/IC50) (r2=0.76, r(cv)2=0.64). An external test for the models was performed on a dataset of 18 molecules with IC50 values >1 microM. Fourteen of these were correctly classified. Classification ability of various models, including self-organizing maps (SOM), for all 60 molecules was also evaluated. A detailed analysis of the modeling results revealed the following relative contributions of the used descriptors to the trained ANN QSAR model: approximately 44.0% from the length of the N-alkyl chain attached to the quaternary ammonium head group, approximately 20.0% from Moriguchi octanol-water partition coefficient of the molecule, approximately 13.0% from molecular surface area, approximately 12.6% from the first component shape directional WHIM index/unweighted, approximately 7.8% from Ghose-Crippen molar refractivity, and 2.6% from the lowest unoccupied molecular orbital energy. The ANN QSAR models were also evaluated using a set of 13 newly synthesized compounds (11 biologically active antagonists and two biologically inactive compounds) whose structures had not been previously utilized in the training set. Twelve among 13 compounds were predicted to be active which further supports the robustness of the trained models. Other insights from modeling include a structural modification in the bis-quinolinium series that involved replacing the 5 and/or 8 as well as the 5' and/or 8' carbon atoms with nitrogen atoms, predicting inactive compounds. Such data can be effectively used to reduce synthetic and in vitro screening activities by eliminating compounds of predicted low activity from the pool of candidate molecules for synthesis. The application of the ANN QSAR model has led to the successful discovery of six new compounds in this study with experimental IC50 values of less than 0.1 microM at nAChR subtypes responsible for mediating nicotine-evoked dopamine release, demonstrating that the ANN QSAR model is a valuable aid to drug discovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16431111     DOI: 10.1016/j.bmc.2005.12.036

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2.

Authors:  Fang Zheng; Guangrong Zheng; A Gabriela Deaciuc; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2007-02-11       Impact factor: 3.641

Review 2.  Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

Authors:  Peter A Crooks; Guangrong Zheng; Ashish P Vartak; John P Culver; Fang Zheng; David B Horton; Linda P Dwoskin
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 3.  Nicotinic receptor antagonists as treatments for nicotine abuse.

Authors:  Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

4.  Improved Prediction of Blood-Brain Barrier Permeability Through Machine Learning with Combined Use of Molecular Property-Based Descriptors and Fingerprints.

Authors:  Yaxia Yuan; Fang Zheng; Chang-Guo Zhan
Journal:  AAPS J       Date:  2018-03-21       Impact factor: 4.009

5.  Modeling in vitro inhibition of butyrylcholinesterase using molecular docking, multi-linear regression and artificial neural network approaches.

Authors:  Fang Zheng; Max Zhan; Xiaoqin Huang; Mohamed Diwan M Abdul Hameed; Chang-Guo Zhan
Journal:  Bioorg Med Chem       Date:  2013-11-08       Impact factor: 3.641

6.  Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the alpha4beta2* nicotinic acetylcholine receptor.

Authors:  Fang Zheng; Guangrong Zheng; A Gabriela Deaciuc; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  J Enzyme Inhib Med Chem       Date:  2009-02       Impact factor: 5.051

7.  Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Guangrong Zheng; Sangeetha P Sumithran; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2007-10-22       Impact factor: 2.823

8.  Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation.

Authors:  Guangrong Zheng; Zhenfa Zhang; Marharyta Pivavarchyk; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2007-10-18       Impact factor: 2.823

9.  QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum.

Authors:  Fang Zheng; Matthew J McConnell; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2009-05-08       Impact factor: 3.641

10.  Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.

Authors:  Linda P Dwoskin; Marharyta Pivavarchyk; B Matthew Joyce; Nichole M Neugebauer; Guangrong Zheng; Zhenfa Zhang; Michael T Bardo; Peter A Crooks
Journal:  Nebr Symp Motiv       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.